PB
PBYI.US Puma Biotechnology Inc
- Market cap
- USD 379M
- P/E
- 16.7x
- P/B
- 2.73x
- ROE
- 9.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PBYI.US undervalued?
Graham numberPBYI.US trades 42.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Puma Biotechnology Inc fundamental analysis
No fundamental analysis for Puma Biotechnology Inc yet.
Puma Biotechnology Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor …
Full company profilePuma Biotechnology Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Puma Biotechnology Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 27.7M | 251M | 272M | 225M | 253M | 228M | 236M | 230M | 228M | 208M |
| Gross Profit | -1.15M | 22.1M | 216M | 235M | 186M | 189M | 173M | 173M | 166M | 170M | 158M |
| Operating Income | -277M | -292M | -94.7M | -75.6M | -30.4M | 1.29M | 23.7M | 32.6M | 31.0M | 37.3M | 12.0M |
| EBITDA | -275M | -288M | -95.2M | -52.4M | -35.7M | -4.69M | 21.9M | 47.5M | 48.1M | 53.3M | 25.9M |
| Net Income | -276M | -292M | -114M | -75.6M | -60.0M | -29.1M | 2.00K | 21.6M | 30.3M | 31.1M | 13.9M |
| EPS | -8.29 | -7.86 | -2.99 | -1.95 | -1.52 | -0.72 | 0.00 | 0.45 | 0.62 | 0.61 | 0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 253M | 166M | 259M | 235M | 244M | 227M | 222M | 231M | 213M | 216M | 203M |
| Total Liabilities | 43.0M | 112M | 225M | 217M | 250M | 229M | 200M | 177M | 121M | 86.0M | 56.2M |
| Shareholders' Equity | 210M | 53.3M | 34.3M | 17.5M | -5.95M | -2.45M | 21.6M | 53.4M | 92.1M | 130M | 147M |
| Cash & Short-term Investments | 195M | 81.7M | 108M | 112M | 93.4M | 82.1M | 81.1M | 95.9M | 101M | 97.5M | 109M |
| Total Debt | - | 48.5M | 152M | 120M | 121M | 117M | 114M | 111M | 74.1M | 28.5M | 4.87M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -142M | -173M | -24.1M | 22.4M | 800K | 20.7M | -15.8M | 27.0M | 38.9M | 41.8M | 42.2M |
| Capital Expenditure | 7.28M | 50.4M | 609K | 306K | 20.0M | 1.00K | 7.00M | 12.6M | 56.0K | 71.0K | 0.00 |
| Free Cash Flow | -149M | -223M | -24.7M | 22.1M | -19.2M | 20.6M | -22.8M | 14.4M | 38.9M | 41.7M | 42.2M |
| Ratios | |||||||||||
| ROE | -131.6% | -547.8% | -331.1% | -432.9% | - | - | 0.0% | 40.4% | 32.9% | 23.9% | 9.5% |
| ROA | -109.2% | -176.4% | -43.8% | -32.2% | -24.6% | -12.9% | 0.0% | 9.4% | 14.2% | 14.4% | 6.8% |
| Net Profit Margin | - | -1,054.2% | -45.3% | -27.8% | -26.7% | -11.5% | 0.0% | 9.2% | 13.1% | 13.6% | 6.6% |
| Debt to Equity | - | 0.91x | 4.43x | 6.88x | - | - | 5.29x | 2.09x | 0.80x | 0.22x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Puma Biotechnology Inc dividends
Puma Biotechnology Inc has not paid dividends in the last 9 fiscal years.
Who owns Puma Biotechnology Inc
- Insiders 15.84%
- Institutions 78.86%
- Public & others 5.31%
- Shares outstanding 51.7M
- Free float 40.4M
Top funds holding PBYI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Avantis US Small Cap Value ETF | 2.48M | 4.80% | +0.50% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.34M | 2.60% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.15M | 2.22% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 777K | 1.50% | 0.00% | Sep 2026 |
| Vanguard Strategic Equity Inv | 540K | 1.05% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 484K | 0.94% | 0.00% | Aug 2026 |
| Bridge Builder Small Cap Fund | 394K | 0.76% | +134.76% | Oct 2026 |
| iShares Russell 2000 Value ETF | 360K | 0.70% | 0.00% | Oct 2026 |
| Northern Small Cap Value | 268K | 0.52% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 257K | 0.50% | +1.11% | Sep 2026 |
| EA Bridgeway Omni Small-Cap Value ETF | 249K | 0.48% | 0.00% | Oct 2026 |
| Russell Inv Tax-Managed US Mid&Sm Cap S | 248K | 0.48% | 0.00% | Sep 2026 |
| DFA U.S. Targeted Value I | 241K | 0.47% | +2.20% | Sep 2026 |
| DFA U.S. Small Cap Value I | 222K | 0.43% | +57.77% | Sep 2026 |
| DFA U.S. Small Cap I | 221K | 0.43% | 0.00% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 220K | 0.43% | +0.27% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 206K | 0.40% | 0.00% | Sep 2026 |
| LSV Small Cap Value Institutional | 202K | 0.39% | +27.29% | Sep 2026 |
| Fidelity Extended Market Index | 176K | 0.34% | +7.89% | Sep 2026 |
| Invesco Dorsey Wright SmallCap Momt ETF | 176K | 0.34% | -0.54% | Oct 2026 |
Top institutions holding PBYI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 3.80M | 7.36% | +5.72% | Jun 2026 |
| American Century Companies Inc | 2.74M | 5.31% | +18.22% | Sep 2026 |
| Acadian Asset Management LLC | 2.08M | 4.03% | +1.49% | Sep 2026 |
| LSV Asset Management | 1.94M | 3.76% | +19.97% | Sep 2026 |
| Renaissance Technologies Corp | 1.88M | 3.64% | +2.60% | Sep 2026 |
| Vanguard Capital Management, LLC | 1.84M | 3.55% | +0.99% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.83M | 3.53% | +5.24% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 1.56M | 3.01% | +2.48% | Sep 2026 |
| Geode Capital Management, LLC | 1.34M | 2.59% | +31.66% | Jun 2026 |
| O'Shaughnessy Asset Management LLC | 1.12M | 2.17% | -1.26% | Jun 2026 |
| State Street Corp | 952K | 1.84% | +3.77% | Jun 2026 |
| Kennedy Capital Management Inc | 873K | 1.69% | -1.84% | Jun 2026 |
| Bridgeway Capital Management, LLC | 792K | 1.53% | +2.10% | Jun 2026 |
| Comprehensive Portfolio Management, LLC | 750K | 1.45% | -3.17% | Jun 2026 |
| AQR Capital Management LLC | 725K | 1.40% | -9.37% | Jun 2026 |
| The Goldman Sachs Group Inc | 669K | 1.29% | -0.08% | Jun 2026 |
| Northern Trust Corp | 652K | 1.26% | +1.66% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 643K | 1.24% | -17.87% | Jun 2026 |
| UBS Group AG | 637K | 1.23% | +19.19% | Jun 2026 |
| Millennium Management LLC | 602K | 1.17% | -59.24% | Jun 2026 |
Puma Biotechnology Inc company profile
- Company name
- Puma Biotechnology Inc
- Ticker
- PBYI.US
- Exchange
- USA Stocks
- Listed since
- Apr 24, 2012
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 179
- Fiscal year end
- December
- Address
- 10880 Wilshire Boulevard, Los Angeles, CA, United States, 90024
- Phone
- 424 248 6500
- Website
- pumabiotechnology.com
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Puma Biotechnology Inc management
10- Mr. Alan H. AuerbachFounder, Chairman, President, CEO & Secretary · born 1970
- Mr. Maximo F. NouguesCFO & Principal Accounting Officer · born 1969
- Mr. Douglas Hunt B.Sc., FRAPSChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer · born 1965
- Mr. Gordon G. EsplinChief Accounting Officer · born 1968
- Mr. Mariann OhanesianSenior Director of Investor Relations
- Ms. Heather BlaberSenior Vice President of Marketing
- Mr. Roger L. StormsSenior Vice President of Sales
- Ms. Pamela Wilson BASenior Vice President of Clinical Operations
- Dr. Petra RietschelSenior Vice President of Clinical Development
- Mr. Kenneth WieheSenior Vice President of Supply Chain & Manufacturing